Want to see AU:IVX full AI Analyst Report?
Top Page
Invion
(Sydney:IVX)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.04
▲(0.00% Upside)
Action:Reiterated
Date:10/06/26
The score is weighed down primarily by weak financial performance: persistent losses, unstable revenue base, ongoing cash burn, and material equity erosion that increases funding risk. Technicals add only limited support (short-term price above several moving averages) but remain weak on momentum with the stock still far below the 200-day average. Valuation is also constrained because losses drive a negative P/E and there is no dividend yield provided.
Positive Factors
Focused oncology pipeline
A focused oncology platform gives Invion a clear strategic identity and concentrates its limited resources on a defined therapeutic approach. If development continues successfully, IVX-P02 could support expansion across multiple cancer indications and create a basis for partner-led commercialisation.
Negative Factors
Persistent unprofitability
Recurring operating and net losses show that Invion has not yet converted its development activities into a profitable business. Continued losses can consume capital, constrain investment choices, and increase dependence on future funding or commercial milestones before the model can become self-sustaining.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused oncology pipeline
A focused oncology platform gives Invion a clear strategic identity and concentrates its limited resources on a defined therapeutic approach. If development continues successfully, IVX-P02 could support expansion across multiple cancer indications and create a basis for partner-led commercialisation.
Read all positive factors
Invion (IVX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.59M
Dividend YieldN/A
Average Volume (3M)64.14K
Price to Earnings (P/E)―
Beta (1Y)-0.50
Revenue GrowthN/A
EPS Growth48.77%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.06
Shares Outstanding109,200,640
10 Day Avg. Volume89,972
30 Day Avg. Volume64,135
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.17
P/FCF Ratio-1.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Invion Business Overview & Revenue Model
Company Description
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent be...
How the Company Makes Money
null...
Invion Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
47
Neutral
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 385.32K | 0.00 | 3.69M | 4.10M | 3.29M |
| Gross Profit | 385.32K | -1.29M | 1.00M | 1.21M | 969.12K |
| EBITDA | -3.94M | -4.00M | -4.57M | -965.37K | -1.82M |
| Net Income | -5.63M | -8.81M | -5.63M | -1.61M | -2.24M |
Balance Sheet | |||||
| Total Assets | 8.17M | 9.49M | 15.45M | 19.05M | 20.04M |
| Cash, Cash Equivalents and Short-Term Investments | 592.31K | 850.37K | 783.53K | 4.08M | 8.47M |
| Total Debt | 1.55M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.85M | 1.24M | 1.01M | 650.63K | 462.41K |
| Stockholders Equity | 5.32M | 8.25M | 14.44M | 18.40M | 19.58M |
Cash Flow | |||||
| Free Cash Flow | -2.38M | -2.97M | -3.30M | -4.39M | -8.36M |
| Operating Cash Flow | -2.37M | -2.97M | -2.40M | -1.81M | -1.11M |
| Investing Cash Flow | -68.83K | 0.00 | -900.00K | -2.58M | -7.25M |
| Financing Cash Flow | 2.18M | 3.04M | 0.00 | 15.80M | 15.80M |
Invion Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.04
Positive
0.06
Negative
Market Momentum
<0.01
Negative
59.22
Neutral
94.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IVX, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.22 is Neutral, neither overbought nor oversold. The STOCH value of 94.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IVX.
Invion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$47.88M | 75.00 | 1.13% | 0.49% | 8.99% | 450.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$16.55M | -5.94 | -13.81% | 6.27% | 5.93% | 66.32% | |
45 Neutral | AU$7.29M | -0.73 | -65.33% | ― | ― | 72.60% | |
42 Neutral | AU$4.59M | -0.64 | -102.18% | ― | ― | 48.77% | |
40 Underperform | AU$4.01M | -0.32 | 102.60% | ― | 17.56% | 75.11% | |
39 Underperform | AU$21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
AU:IVX
Invion
0.04
-0.06
-58.00%
AU:PER
Percheron Therapeutics
―
―
―
AU:RGT
Argent Biopharma
0.03
-0.06
-63.83%
AU:MVP
Medical Developments International Limited
0.43
-0.22
-33.59%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-20.00%
AU:IDT
IDT Australia Limited
0.04
-0.02
-36.67%
Invion Corporate Events
Invion Plans ASX Share Placement to Boost Capital
Sep 29, 2026
Invion Limited has notified the ASX of a proposed placement involving up to 8,218,000 ordinary fully paid shares. The new securities are expected to be issued on Dec. 4, 2026, and will be quoted on the ASX subject to compliance with listing rules....
Invion Secures $400,000 in Director Loans to Support Working Capital
Sep 29, 2026
Invion has secured short-term funding support from two board members through unsecured director loans totaling $400,000 to bolster working capital. Executive Chair and CEO Prof Thian Chew and Non-Executive Director Alan Yamashita have each committ...
Invion Sets Out 2026 Governance Framework and Board Changes
Aug 26, 2026
Invion has detailed its corporate governance practices for the financial year ended 30 June 2026, outlining the composition of its four-member Board and recent changes, including the resignation of a non-executive director and the appointment of P...
Invion Narrows Annual Loss but Net Tangible Assets Slide Deeper Into Negative Territory
Aug 26, 2026
Invion Limited reported revenue of $384,707 for the year ended 30 June 2026 and a reduced net loss of $5.63 million, down 36% from the prior year, with no dividends declared. Despite the improved bottom line, net tangible assets per share fell fur...
Invion Appoints New Director With No Current Securities Interests
Aug 20, 2026
Invion Limited has appointed Paul Hilton Field as a director effective 18 August 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Field currently holds no relevant interests in Invion sec...
Invion strengthens clinical leadership and expands Photosoft into new cancer and eye indications
Jul 31, 2026
Invion reported a modest improvement in quarterly cash reserves to $592,000, supported by expected RD tax incentive receipts and disciplined spending on research and corporate costs. The company also disclosed related‑party payments of $66,0...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.